Eur Rev Med Pharmacol Sci 2022; 26 (16): 5911-5917

DOI: 10.26355/eurrev_202208_29530

Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). a case report

L. Valdenassi, E. Rossi, M.T. Corsetti, R. Sarli, D. Bellardi, S. Chirumbolo, V. Simonetti, S. Pandolfi, M. Franzini

Italian Society of Oxygen-Ozone Therapy (SIOOT), Gorle (BG), Italy. salvatore.chirumbolo@univr.it


OBJECTIVE: Sjögren syndrome (SS) is an autoimmune disorder, affecting about 16,000 individuals in Italy, yet lacking a standardized therapy protocol and a plain inclusion in the reimbursed healthcare services. This raises many controversial issues about how managing the SS patient, to relief pain and discomfort and improve patients’ health and social life. The ozone therapy resulted successful in previous reports, and therefore, it was used in this case report.

CASE PRESENTATION: A 69-years old female outpatient, showing positivity to Schirmer’s test, was previously diagnosed as a primary Sjögren syndrome, who later developed an autoimmune thyroiditis and showed the presence of rheumatoid factors. The patient suffered from a marked ocular dryness, subsequently to a purported endothelitis, alongside with fatigue and pain. Laboratory tests showed a positive ANA 1:320 in a speckled pattern with negative anti-SSA and anti-SSB tests. From December 2020 to January 2021 she underwent 2 routes of three sessions of oxygen-ozone autohemotherapy (O2-O3 AHT), as described below and improved, with only 2 sessions, her symptomatology and clinical outcome, as ocular dryness, fatigue and pain, rapidly disappeared.

CONCLUSIONS: The use of ozone in the therapy of SS is a straightforward, affordable and feasible approach to treat primary Sjögren syndrome without significant side effects.

Free PDF Download

To cite this article

L. Valdenassi, E. Rossi, M.T. Corsetti, R. Sarli, D. Bellardi, S. Chirumbolo, V. Simonetti, S. Pandolfi, M. Franzini
Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). a case report

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 16
Pages: 5911-5917
DOI: 10.26355/eurrev_202208_29530